Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 3/20 | 0.52 |
| ▸ | CDC25B | P30305 | 1/20 | 0.52 |
| ▸ | CYP24A1 | Q07973 | 4/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 9/20 | 0.42 |
| ▸ | VDR | P11473 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.38 |
| ▸ | CYP27B1 | O15528 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10353003 | 0.90 | CDC25A (0.51) | CDC25ACDC25BCYP24A1NR1H4CA1 | |
| SCHEMBL5066627 | 0.83 | CDC25A (0.41) | CDC25ACDC25BCYP24A1NR1H4VDR | |
| SCHEMBL12489329 | 0.83 | CYP24A1 (0.59) | CDC25ACDC25BCYP24A1NR1H4VDR | |
| SCHEMBL12489598 | 0.83 | CYP24A1 (0.59) | CDC25ACDC25BCYP24A1NR1H4VDR | |
| SCHEMBL12487933 | 0.82 | CYP24A1 (0.55) | CDC25ACDC25BCYP24A1NR1H4CYP27B1 | |
| SCHEMBL12408048 | 0.82 | CYP24A1 (0.55) | CDC25ACDC25BCYP24A1NR1H4CYP27B1 | |
| SCHEMBL16317533 | 0.81 | CDC25A (0.42) | CDC25ACDC25BCYP24A1NR1H4VDR | |
| SCHEMBL25479009 | 0.77 | GPBAR1 (0.64) | NR1H4VDRGPBAR1CA1CA2 | |
| SCHEMBL20087697 | 0.77 | GPBAR1 (0.64) | NR1H4VDRGPBAR1CA1CA2 | |
| SCHEMBL19430542 | 0.77 | GPBAR1 (0.64) | NR1H4VDRGPBAR1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1061070-B1 | Process for the preparation of ED-71 | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-6538145-B2 | Having a hydroxy group at 24-position and, optionally, a substituent at 2 beta position; reacting intermediates of the A ring part and intermediates of the C ring; cyclization; coupling; control of calcium metabolism; antitumor agents | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-25 | — | — | US | disclosed |
| US-20020094972-A1 | 24-hydroxy vitamin D derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-07-18 | — | — | US | disclosed |
| EP-1061070-A1 | 24-HYDROXYVITAMIN D DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094972-A1 | 24-hydroxy vitamin D derivatives | CYP24A1, VDR, CYP2R1 | CDC25A 1723/4885CDC25B 2256/4885CYP24A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.